Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) EBIT (2016 - 2025)

Historic EBIT for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $18.6 million.

  • Macrogenics' EBIT fell 6561.05% to $18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.6 million, marking a year-over-year decrease of 605.92%. This contributed to the annual value of -$110.6 million for FY2024, which is 3427.52% up from last year.
  • As of Q3 2025, Macrogenics' EBIT stood at $18.6 million, which was down 6561.05% from -$36.8 million recorded in Q2 2025.
  • Macrogenics' EBIT's 5-year high stood at $54.2 million during Q3 2024, with a 5-year trough of -$66.6 million in Q1 2022.
  • In the last 5 years, Macrogenics' EBIT had a median value of -$42.6 million in 2025 and averaged -$34.9 million.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 258368.66% in 2021, then soared by 25264.21% in 2024.
  • Over the past 5 years, Macrogenics' EBIT (Quarter) stood at -$58.2 million in 2021, then soared by 120.58% to $12.0 million in 2022, then plummeted by 511.87% to -$49.4 million in 2023, then decreased by 7.06% to -$52.8 million in 2024, then soared by 135.27% to $18.6 million in 2025.
  • Its EBIT was $18.6 million in Q3 2025, compared to -$36.8 million in Q2 2025 and -$42.6 million in Q1 2025.